Jazz Pharmaceuticals (JAZZ) Enterprise Value (2010 - 2026)

Jazz Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.8 billion for Q1 2026.

• In Q1 2026, Enterprise Value rose 0.95% year-over-year to -$1.8 billion; the TTM figure through Mar 2026 stood at -$1.8 billion (up 0.95% YoY), while the FY2025 annual figure was -$1.4 billion, up 42.31% from the prior year.
• Enterprise Value was -$1.8 billion for Q1 2026 at Jazz Pharmaceuticals, down from -$1.4 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$490.8 million in Q1 2022 to a low of -$2.4 billion in Q4 2024.
• Historically, Enterprise Value has averaged -$1.4 billion across 5 years, with a median of -$1.3 billion in 2023.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 76.6% in 2022, then tumbled 137.94% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$881.5 million in 2022, then slumped by 70.88% to -$1.5 billion in 2023, then tumbled by 60.18% to -$2.4 billion in 2024, then surged by 42.31% to -$1.4 billion in 2025, then plunged by 32.5% to -$1.8 billion in 2026.
• The last three Enterprise Value figures came in at -$1.8 billion (Q1 2026), -$1.4 billion (Q4 2025), and -$1.3 billion (Q3 2025), per Business Quant data.